Brokerages Set Atyr PHARMA INC (NASDAQ:ATYR) Target Price at $19.25

Atyr PHARMA INC (NASDAQ:ATYR) has received an average rating of “Buy” from the seven brokerages that are presently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $18.60.

Several analysts have weighed in on the company. Leerink Partnrs upgraded Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of Atyr PHARMA in a report on Tuesday, December 10th. Leerink Partners started coverage on shares of Atyr PHARMA in a report on Tuesday. They issued an “outperform” rating and a $16.00 price objective for the company. Finally, Cantor Fitzgerald initiated coverage on shares of Atyr PHARMA in a research note on Monday, January 6th. They set an “overweight” rating on the stock.

Institutional Trading of Atyr PHARMA

Institutional investors and hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. raised its stake in Atyr PHARMA by 52.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock valued at $55,000 after purchasing an additional 10,754 shares during the last quarter. Alterna Wealth Management Inc. acquired a new stake in shares of Atyr PHARMA in the fourth quarter valued at about $36,000. Kingswood Wealth Advisors LLC purchased a new position in shares of Atyr PHARMA in the fourth quarter worth about $170,000. American Century Companies Inc. acquired a new position in Atyr PHARMA during the fourth quarter worth about $319,000. Finally, Raymond James Financial Inc. purchased a new stake in Atyr PHARMA during the 4th quarter valued at about $39,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Atyr PHARMA Stock Up 4.4 %

NASDAQ:ATYR opened at $4.44 on Tuesday. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. The company’s 50 day moving average is $3.58 and its two-hundred day moving average is $2.86. Atyr PHARMA has a twelve month low of $1.42 and a twelve month high of $4.57. The company has a market cap of $372.27 million, a PE ratio of -4.72 and a beta of 1.10.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.